Both in vitro and in vivo studies have demonstrated that tyrosinase inhibitors not only suppress melanin biosynthesis but also enhance the sensitivity of melanoma cells to chemotherapy and radiotherapy, thereby improving therapeutic efficacy. The gene discussed is TYR; the disease is melanoma.